Promus Element stent (Boston Scientific) continues to outperform the Xience V stent at 3 years

At three years, the Promus Element everolimus eluting stent, from Boston Scientific, continued to demonstrate advantages for CAD patients over the Xience V Stent. The trial reported a three-year target lesion revascularization (TLR) rate of 3.5 percent for the Promus Element Stent, the lowest TLR rate in any pivotal FDA approval trial, compared to 4.9 percent for the Xience V Stent (p=0.21). Both the Promus Element and Xience V Stents demonstrated low rates of ARC/Definite stent thrombosis of 0.7 percent and 0.5 percent respectively (p=0.76). Trial results also confirmed a previously reported significant reduction in unplanned (bail-out or emergency) stenting with the Promus Element Stent compared to the Xience V Stent (5.9 percent vs. 9.8 percent, p=0.004), including a significantly lower rate of inadequate lesion coverage (1.4 percent vs. 3.4 percent, p=0.01). Data were presented today by Ian Meredith, M.D., Monash University, Melbourne, Australia, at the 62nd Annual Scientific Session of the American College of Cardiology.